You are viewing: GCC Countries Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The GCC Countries Plasma Fractionation Market was valued at $282.4 Million in 2026 and projected to reach to $359.8 Million by 2031, representing a compound annual growth rate of 5.0%. The GCC Countries plasma fractionation market is poised for steady growth through 2031, driven by expanding healthcare infrastructure investments and rising patient awareness of plasma-derived therapeutics.

GCC Countries Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

GCC Countries Plasma Fractionation Market Trends and Insights

  • GCC Countries are experiencing steady expansion in plasma-derived therapeutics driven by increasing healthcare infrastructure investment and rising demand for immunoglobulin and clotting factor treatments.
  • The region's healthcare systems are modernizing rapidly, with GCC Countries prioritizing self-sufficiency in blood plasma collection and fractionation capabilities to reduce import dependency. GCC Countries benefit from strong government healthcare spending and a growing patient population requiring plasma-derived medicines for immunodeficiency, hemophilia, and other bleeding disorders.
  • The market in GCC Countries is characterized by a mix of domestic production initiatives and partnerships with international plasma fractionation manufacturers.
  • Over the forecast period from 2026 to 2031, GCC Countries are expected to see increased adoption of advanced fractionation technologies and expanded plasma collection networks, supporting the projected market growth..

Key Market Statistics

  • CAGR (2026-2031) 5.0% CAGR
  • Market Size, 2026 ~USD 282.4 Million
  • Forecast, 2031 ~USD 359.8 Million
  • Country GCC Countries

GCC Countries Plasma Fractionation Market Overview

Market Size & Growth :

GCC Countries plasma fractionation market valued at USD 282.4 million in 2026, expanding to USD 359.8 million by 2031 at a steady 5.0% CAGR, reflecting consistent regional demand for plasma-derived therapeutics.

Healthcare Infrastructure Investment :

GCC nations are significantly investing in advanced healthcare facilities and blood banking infrastructure, creating favorable conditions for plasma fractionation product adoption and distribution across the region.

Rising Immunoglobulin Demand :

Increasing prevalence of immunodeficiency disorders and autoimmune diseases in GCC Countries is driving substantial demand for immunoglobulin products, a key segment within plasma fractionation therapeutics.

Clotting Factor Therapeutics Growth :

Growing awareness and diagnosis of bleeding disorders across GCC Countries is propelling demand for clotting factor concentrates, supported by improved healthcare accessibility and diagnostic capabilities.

GCC Countries Plasma Fractionation Market Dynamics

  • Government initiatives to enhance blood collection and processing capabilities, combined with increasing prevalence of hemophilia and immunodeficiency disorders, are creating robust market opportunities.
  • The region's high healthcare spending and focus on advanced treatment options support market expansion. Key growth drivers include rising demand for immunoglobulin products for immunodeficiency treatment, increased adoption of clotting factor concentrates for bleeding disorder management, and strengthening regulatory frameworks supporting plasma fractionation facilities.
  • Strategic partnerships between regional healthcare providers and international plasma fractionation manufacturers are expected to enhance product availability and market penetration across GCC nations..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • GCC Countries plasma fractionation market valued at USD 282.4 million in 2026, growing at 5.0% CAGR through 2031.
      • GCC Countries are investing in domestic plasma collection and fractionation infrastructure to achieve healthcare self-sufficiency.
      • Rising prevalence of bleeding disorders and immunodeficiency conditions is driving demand for plasma-derived therapeutics in GCC Countries.
      • GCC Countries market characterized by strategic partnerships between local healthcare providers and international plasma fractionation manufacturers.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      GCC Countries Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Plasma Fractionation Manufacturers : Manufacturers need GCC-specific market data to evaluate regional expansion opportunities, assess competitive positioning, and develop localized product strategies for immunoglobulin and clotting factor segments.
      • Healthcare Investment Firms : Investment professionals require detailed GCC market analysis to identify high-potential acquisition targets, evaluate portfolio companies' regional growth prospects, and make informed capital allocation decisions.
      • Hospital & Blood Bank Operators : Healthcare facility operators need market insights to optimize plasma fractionation product procurement, understand demand trends, and plan infrastructure investments aligned with regional market growth.
      • Pharmaceutical Distributors & Wholesalers : Distribution partners require GCC market intelligence to forecast demand, optimize inventory management, identify supplier partnerships, and develop effective go-to-market strategies for plasma products.
      • Government & Healthcare Policy Makers : Policy officials need comprehensive market data to inform healthcare regulations, blood safety standards, and strategic initiatives supporting plasma fractionation industry development in GCC nations.

      Reasons to Buy this Report

      • Regional Market Sizing & Forecasting : Obtain precise market valuation for GCC Countries (USD 282.4M in 2026) with detailed 5-year forecasts, enabling accurate budget allocation and investment planning specific to this high-growth healthcare region.
      • Competitive Landscape Intelligence : Understand market dynamics, key players, and competitive positioning within GCC Countries plasma fractionation sector to identify partnership opportunities and market entry strategies tailored to regional conditions.
      • Segment-Specific Insights : Access detailed analysis of immunoglobulin and clotting factor segments within GCC Countries, including demand drivers, adoption rates, and growth trajectories to optimize product portfolio strategies.
      • Regulatory & Healthcare Infrastructure Analysis : Gain comprehensive understanding of GCC regulatory frameworks, healthcare infrastructure investments, and government initiatives supporting plasma fractionation market development and commercialization.
      • Strategic Market Entry Planning : Leverage GCC-specific market insights to develop targeted go-to-market strategies, identify distribution channels, and assess reimbursement landscapes for successful regional market penetration.

      Frequently asked questions

      What is the current market size of plasma fractionation in GCC Countries?

      The plasma fractionation market in GCC Countries is estimated at USD 282.4 million in 2026.

      What is the projected market size for plasma fractionation in GCC Countries by 2031?

      GCC Countries plasma fractionation market is projected to reach USD 359.8 million by 2031.

      What is the CAGR for plasma fractionation in GCC Countries?

      The plasma fractionation market in GCC Countries is expected to grow at a CAGR of 5.0% from 2026 to 2031.

      What are the main drivers of growth in GCC Countries plasma fractionation market?

      Key growth drivers in GCC Countries include increased healthcare infrastructure investment, rising demand for immunoglobulin and clotting factors, and government initiatives to develop domestic plasma fractionation capabilities.

      Why are GCC Countries investing in domestic plasma fractionation?

      GCC Countries are prioritizing domestic plasma collection and fractionation to reduce import dependency, enhance healthcare self-sufficiency, and ensure stable supply of plasma-derived therapeutics.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status